Received Sep 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
have not received the third dose so far; Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 44-year-old female patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (Received 1st dose of Twinrix vaccine on 22-MAR-2017). On 05-OCT-2017, the patient received the 2nd dose of Twinrix. The patient did not receive the 3rd dose of Twinrix. On 05-OCT-2017, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: have not received the third dose so far). The outcome of the drug dose administration interval too long and incomplete course of vaccination was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-AUG-2025 A patient got first dose of Twinrix on 22-Mar-2017 and second dose on 05-Oct-2017 and did not receive the third dose so far.